Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Neuromedin U and Structural Analogs: An Overview of their Structure, Function and Selectivity

Author(s): An De Prins, Ann Van Eeckhaut*, Ilse Smolders*, Dirk Tourwé and Steven Ballet*

Volume 27, Issue 39, 2020

Page: [6744 - 6768] Pages: 25

DOI: 10.2174/0929867326666190916143028

Price: $65

Abstract

The neuromedin U peptide sequence is highly conserved between various species. Neuromedin U is involved in a variety of physiological processes. It exerts its effects via two neuromedin U receptors, NMUR1 and NMUR2. These receptors are characterized by a distinct, yet complementary, tissue distribution with NMUR1 mostly found in the periphery, while NMUR2 is most abundant in the central nervous system. The capability of the neuropeptide to reduce food intake in rodents triggered the design and synthesis of a broad range of modified peptide ligands. The purpose of these ligands is to develop novel therapeutics which could be beneficial in the treatment of obesity and diabetes. Most compounds are derived either from the full-length neuromedin U sequence or are based on the truncated orthologs of this neuropeptide. Only a few non-peptidic ligands were developed. This review provides an overview on various neuromedin U analogs and mimetics that have been reported to date.

Keywords: Neuromedin U, neuromedin U receptor 1, neuromedin U receptor 2, agonist, antagonist, analog, peptidomimetic.

« Previous
[1]
Kangawa, K.; Minamino, N.; Fukuda, A.; Matsuo, H. Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem. Biophys. Res. Commun., 1983, 114(2), 533-540.
[http://dx.doi.org/10.1016/0006-291X(83)90813-6] [PMID: 6576785]
[2]
Minamino, N.; Kangawa, K.; Matsuo, H. Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem. Biophys. Res. Commun., 1983, 114(2), 541-548.
[http://dx.doi.org/10.1016/0006-291X(83)90814-8] [PMID: 6882442]
[3]
Minamino, N.; Kangawa, K.; Matsuo, H. Neuromedin C: a bombesin-like peptide identified in porcine spinal cord. Biochem. Biophys. Res. Commun., 1984, 119(1), 14-20.
[http://dx.doi.org/10.1016/0006-291X(84)91611-5] [PMID: 6546686]
[4]
Minamino, N.; Kangawa, K.; Fukuda, A.; Matsuo, H. Neuromedin L: a novel mammalian tachykinin identified in porcine spinal cord. Neuropeptides, 1984, 4(2), 157-166.
[http://dx.doi.org/10.1016/0143-4179(84)90126-4] [PMID: 6144073]
[5]
Minamino, N.; Kangawa, K.; Matsuo, H. Neuromedin N: a novel neurotensin-like peptide identified in porcine spinal cord. Biochem. Biophys. Res. Commun., 1984, 122(2), 542-549.
[http://dx.doi.org/10.1016/S0006-291X(84)80067-4] [PMID: 6547840]
[6]
Minamino, N.; Kangawa, K.; Matsuo, H. Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. Biochem. Biophys. Res. Commun., 1985, 130(3), 1078-1085.
[http://dx.doi.org/10.1016/0006-291X(85)91726-7] [PMID: 3839674]
[7]
Mori, K.; Miyazato, M.; Ida, T.; Murakami, N.; Serino, R.; Ueta, Y.; Kojima, M.; Kangawa, K. Identification of neuromedin S and its possible role in the mammalian circadian oscillator system. EMBO J., 2005, 24(2), 325-335.
[http://dx.doi.org/10.1038/sj.emboj.7600526] [PMID: 15635449]
[8]
Minamino, N.; Sudoh, T.; Kangawa, K.; Matsuo, H. Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides, 1985, 6(Suppl. 3), 245-248.
[http://dx.doi.org/10.1016/0196-9781(85)90381-X] [PMID: 3841690]
[9]
Malendowicz, L.K.; Ziolkowska, A.; Rucinski, M. Neuromedins U and S involvement in the regulation of the hypothalamo-pituitary-adrenal axis. Front. Endocrinol. (Lausanne), 2012, 3, 156.
[http://dx.doi.org/10.3389/fendo.2012.00156] [PMID: 23227022]
[10]
Hoyer, D.; Bartfai, T. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach. Chem. Biodivers., 2012, 9(11), 2367-2387.
[http://dx.doi.org/10.1002/cbdv.201200288] [PMID: 23161624]
[11]
Hökfelt, T.; Broberger, C.; Xu, Z.Q.; Sergeyev, V.; Ubink, R.; Diez, M. Neuropeptides--an overview. Neuropharmacology, 2000, 39(8), 1337-1356.
[http://dx.doi.org/10.1016/S0028-3908(00)00010-1] [PMID: 10818251]
[12]
O’Harte, F.; Bockman, C.S.; Abel, P.W.; Conlon, J.M. Isolation, structural characterization and pharmacological activity of dog neuromedin U. Peptides, 1991, 12(1), 11-15.
[http://dx.doi.org/10.1016/0196-9781(91)90159-M] [PMID: 2052487]
[13]
Fisher, J.M.; Scheller, R.H. Prohormone processing and the secretory pathway. J. Biol. Chem., 1988, 263(32), 16515-16518.
[PMID: 3053690]
[14]
Eberlein, G.A.; Eysselein, V.E.; Davis, M.T.; Lee, T.D.; Shively, J.E.; Grandt, D.; Niebel, W.; Williams, R.; Moessner, J.; Zeeh, J. Patterns of prohormone processing. Order revealed by a new procholecystokinin-derived peptide. J. Biol. Chem., 1992, 267(3), 1517-1521.
[PMID: 1370477]
[15]
Salmon, A.L.; Johnsen, A.H.; Bienert, M.; McMurray, G.; Nandha, K.A.; Bloom, S.R.; Shaw, C. Isolation, structural characterization, and bioactivity of a novel neuromedin U analog from the defensive skin secretion of the Australasian tree frog, Litoria caerulea. J. Biol. Chem., 2000, 275(7), 4549-4554.
[http://dx.doi.org/10.1074/jbc.275.7.4549] [PMID: 10671478]
[16]
Lee, W.H.; Liu, S.B.; Shen, J.H.; Jin, Y.; Lai, R.; Zhang, Y. Identification and molecular cloning of a novel neuromedin U analog from the skin secretions of toad Bombina maxima. Regul. Pept., 2005, 129(1-3), 43-47.
[http://dx.doi.org/10.1016/j.regpep.2005.01.007] [PMID: 15927697]
[17]
Shousha, S.; Nakahara, K.; Miyazato, M.; Kangawa, K.; Murakami, N. Endogenous neuromedin U has anorectic effects in the Japanese quail. Gen. Comp. Endocrinol., 2005, 140(3), 156-163.
[http://dx.doi.org/10.1016/j.ygcen.2004.11.002] [PMID: 15639143]
[18]
Maruyama, K.; Konno, N.; Ishiguro, K.; Wakasugi, T.; Uchiyama, M.; Shioda, S.; Matsuda, K. Isolation and characterisation of four cDNAs encoding neuromedin U (NMU) from the brain and gut of goldfish, and the inhibitory effect of a deduced NMU on food intake and locomotor activity. J. Neuroendocrinol., 2008, 20(1), 71-78.
[http://dx.doi.org/10.1111/j.1365-2826.2007.01615.x ] [PMID: 18081554]
[19]
Brighton, P.J.; Szekeres, P.G.; Willars, G.B. Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol. Rev., 2004, 56(2), 231-248.
[http://dx.doi.org/10.1124/pr.56.2.3] [PMID: 15169928]
[20]
Szekeres, P.G.; Muir, A.I.; Spinage, L.D.; Miller, J.E.; Butler, S.I.; Smith, A.; Rennie, G.I.; Murdock, P.R.; Fitzgerald, L.R.; Wu, Hl.; McMillan, L.J.; Guerrera, S.; Vawter, L.; Elshourbagy, N.A.; Mooney, J.L.; Bergsma, D.J.; Wilson, S.; Chambers, J.K. Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3. J. Biol. Chem., 2000, 275(27), 20247-20250.
[http://dx.doi.org/10.1074/jbc.C000244200] [PMID: 10811630]
[21]
Howard, A.D.; Wang, R.; Pong, S.S.; Mellin, T.N.; Strack, A.; Guan, X.M.; Zeng, Z.; Williams, D.L., Jr; Feighner, S.D.; Nunes, C.N.; Murphy, B.; Stair, J.N.; Yu, H.; Jiang, Q.; Clements, M.K.; Tan, C.P.; McKee, K.K.; Hreniuk, D.L.; McDonald, T.P.; Lynch, K.R.; Evans, J.F.; Austin, C.P.; Caskey, C.T.; Van der Ploeg, L.H.; Liu, Q. Identification of receptors for neuromedin U and its role in feeding. Nature, 2000, 406(6791), 70-74.
[http://dx.doi.org/10.1038/35017610] [PMID: 10894543]
[22]
Martinez, V.G.; O’Driscoll, L. Neuromedin U: a multifunctional neuropeptide with pleiotropic roles. Clin. Chem., 2015, 61(3), 471-482.
[http://dx.doi.org/10.1373/clinchem.2014.231753] [PMID: 25605682]
[23]
Fujii, R.; Hosoya, M.; Fukusumi, S.; Kawamata, Y.; Habata, Y.; Hinuma, S.; Onda, H.; Nishimura, O.; Fujino, M. Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3. J. Biol. Chem., 2000, 275(28), 21068-21074.
[http://dx.doi.org/10.1074/jbc.M001546200] [PMID: 10783389]
[24]
Hosoya, M.; Moriya, T.; Kawamata, Y.; Ohkubo, S.; Fujii, R.; Matsui, H.; Shintani, Y.; Fukusumi, S.; Habata, Y.; Hinuma, S.; Onda, H.; Nishimura, O.; Fujino, M. Identification and functional characterization of a novel subtype of neuromedin U receptor. J. Biol. Chem., 2000, 275(38), 29528-29532.
[http://dx.doi.org/10.1074/jbc.M004261200] [PMID: 10887190]
[25]
Raddatz, R.; Wilson, A.E.; Artymyshyn, R.; Bonini, J.A.; Borowsky, B.; Boteju, L.W.; Zhou, S.; Kouranova, E.V.; Nagorny, R.; Guevarra, M.S.; Dai, M.; Lerman, G.S.; Vaysse, P.J.; Branchek, T.A.; Gerald, C.; Forray, C.; Adham, N. Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. J. Biol. Chem., 2000, 275(42), 32452-32459.
[http://dx.doi.org/10.1074/jbc.M004613200] [PMID: 10899166]
[26]
Hedrick, J.A.; Morse, K.; Shan, L.; Qiao, X.; Pang, L.; Wang, S.; Laz, T.; Gustafson, E.L.; Bayne, M.; Monsma, F.J. Jr. Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U. Mol. Pharmacol., 2000, 58(4), 870-875.
[http://dx.doi.org/10.1124/mol.58.4.870] [PMID: 10999960]
[27]
Kojima, M.; Haruno, R.; Nakazato, M.; Date, Y.; Murakami, N.; Hanada, R.; Matsuo, H.; Kangawa, K. Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). Biochem. Biophys. Res. Commun., 2000, 276(2), 435-438.
[http://dx.doi.org/10.1006/bbrc.2000.3502] [PMID: 11027493]
[28]
Shan, L.; Qiao, X.; Crona, J.H.; Behan, J.; Wang, S.; Laz, T.; Bayne, M.; Gustafson, E.L.; Monsma, F.J. Jr.; Hedrick, J.A. Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. J. Biol. Chem., 2000, 275(50), 39482-39486.
[http://dx.doi.org/10.1074/jbc.C000522200] [PMID: 11010960]
[29]
Aiyar, N.; Disa, J.; Foley, J.J.; Buckley, P.T.; Wixted, W.E.; Pullen, M.; Shabon, U.; Dul, E.; Szekeres, P.G.; Elshourbagy, N.A.; Sarau, H.M.; Appelbaum, E.; Bolaky, J. Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells. Pharmacology, 2004, 72(1), 33-41.
[http://dx.doi.org/10.1159/000078630] [PMID: 15292653]
[30]
Brighton, P.J.; Szekeres, P.G.; Wise, A.; Willars, G.B. Signaling and ligand binding by recombinant neuromedin U receptors: evidence for dual coupling to Galphaq/11 and Galphai and an irreversible ligand-receptor interaction. Mol. Pharmacol., 2004, 66(6), 1544-1556.
[http://dx.doi.org/10.1124/mol.104.002337] [PMID: 15331768]
[31]
Alhosaini, K.; Bahattab, O.; Qassam, H.; Challiss, R.A.J.; Willars, G.B. Ligand-specific signaling profiles and resensitization mechanisms of the neuromedin U2 receptor. Mol. Pharmacol., 2018, 94(1), 674-688.
[http://dx.doi.org/10.1124/mol.117.111070] [PMID: 29724789]
[32]
Brighton, P.J.; Wise, A.; Dass, N.B.; Willars, G.B. Paradoxical behavior of neuromedin U in isolated smooth muscle cells and intact tissue. J. Pharmacol. Exp. Ther., 2008, 325(1), 154-164.
[http://dx.doi.org/10.1124/jpet.107.132803] [PMID: 18180374]
[33]
Dass, N.B.; Bassil, A.K.; North-Laidler, V.J.; Morrow, R.; Aziz, E.; Tuladhar, B.R.; Sanger, G.J. Neuromedin U can exert colon-specific, enteric nerve-mediated prokinetic activity, via a pathway involving NMU1 receptor activation. Br. J. Pharmacol., 2007, 150(4), 502-508.
[http://dx.doi.org/10.1038/sj.bjp.0707004] [PMID: 17211455]
[34]
Maggi, C.A.; Patacchini, R.; Giuliani, S.; Turini, D.; Barbanti, G.; Rovero, P.; Meli, A. Motor response of the human isolated small intestine and urinary bladder to porcine neuromedin U-8. Br. J. Pharmacol., 1990, 99(1), 186-188.
[http://dx.doi.org/10.1111/j.1476-5381.1990.tb14675.x] [PMID: 2331570]
[35]
Prendergast, C.E.; Morton, M.F.; Figueroa, K.W.; Wu, X.; Shankley, N.P. Species-dependent smooth muscle contraction to Neuromedin U and determination of the receptor subtypes mediating contraction using NMU1 receptor knockout mice. Br. J. Pharmacol., 2006, 147(8), 886-896.
[http://dx.doi.org/10.1038/sj.bjp.0706677] [PMID: 16474416]
[36]
Westfall, T.D.; McCafferty, G.P.; Pullen, M.; Gruver, S.; Sulpizio, A.C.; Aiyar, V.N.; Disa, J.; Contino, L.C.; Mannan, I.J.; Hieble, J.P. Characterization of neuromedin U effects in canine smooth muscle. J. Pharmacol. Exp. Ther., 2002, 301(3), 987-992.
[http://dx.doi.org/10.1124/jpet.301.3.987] [PMID: 12023529]
[37]
Okimura, K.; Sakura, N.; Ohta, S.; Kurosawa, K.; Hashimoto, T. Contractile activity of porcine neuromedin U-25 and various neuromedin U-related peptide fragments on isolated chicken crop smooth muscle. Chem. Pharm. Bull. (Tokyo), 1992, 40(6), 1500-1503.
[http://dx.doi.org/10.1248/cpb.40.1500] [PMID: 1394668]
[38]
Sumi, S.; Inoue, K.; Kogire, M.; Doi, R.; Takaori, K.; Suzuki, T.; Yajima, H.; Tobe, T. Effect of synthetic neuromedin U-8 and U-25, novel peptides identified in porcine spinal cord, on splanchnic circulation in dogs. Life Sci., 1987, 41(13), 1585-1590.
[http://dx.doi.org/10.1016/0024-3205(87)90725-9] [PMID: 3626773]
[39]
Gardiner, S.M.; Compton, A.M.; Bennett, T.; Domin, J.; Bloom, S.R. Regional hemodynamic effects of neuromedin U in conscious rats. Am. J. Physiol., 1990, 258(1 Pt 2), R32-R38.
[PMID: 2301645]
[40]
Chu, C.; Jin, Q.; Kunitake, T.; Kato, K.; Nabekura, T.; Nakazato, M.; Kangawa, K.; Kannan, H. Cardiovascular actions of central neuromedin U in conscious rats. Regul. Pept., 2002, 105(1), 29-34.
[http://dx.doi.org/10.1016/S0167-0115(01)00381-0] [PMID: 11853869]
[41]
Jones, N.A.; Morton, M.F.; Prendergast, C.E.; Powell, G.L.; Shankley, N.P.; Hollingsworth, S.J. Neuromedin U stimulates contraction of human long saphenous vein and gastrointestinal smooth muscle in vitro. Regul. Pept., 2006, 136(1-3), 109-116.
[http://dx.doi.org/10.1016/j.regpep.2006.05.003] [PMID: 16782214]
[42]
Mitchell, J.D.; Maguire, J.J.; Kuc, R.E.; Davenport, A.P. Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system. Cardiovasc. Res., 2009, 81(2), 353-361.
[http://dx.doi.org/10.1093/cvr/cvn302] [PMID: 18987052]
[43]
Rahman, A.A.; Shahid, I.Z.; Pilowsky, P.M. Intrathecal neuromedin U induces biphasic effects on sympathetic vasomotor tone, increases respiratory drive and attenuates sympathetic reflexes in rat. Br. J. Pharmacol., 2011, 164(2b), 617-631.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01436.x] [PMID: 21488865]
[44]
Rahman, A.A.; Shahid, I.Z.; Pilowsky, P.M. Differential cardiorespiratory and sympathetic reflex responses to microinjection of neuromedin U in rat rostral ventrolateral medulla. J. Pharmacol. Exp. Ther., 2012, 341(1), 213-224.
[http://dx.doi.org/10.1124/jpet.111.191254] [PMID: 22262923]
[45]
Rahman, A.A.; Shahid, I.Z.; Pilowsky, P.M. Neuromedin U causes biphasic cardiovascular effects and impairs baroreflex function in rostral ventrolateral medulla of spontaneously hypertensive rat. Peptides, 2013, 44, 15-24.
[http://dx.doi.org/10.1016/j.peptides.2013.03.017] [PMID: 23538213]
[46]
Tanida, M.; Satomi, J.; Shen, J.; Nagai, K. Autonomic and cardiovascular effects of central neuromedin U in rats. Physiol. Behav., 2009, 96(2), 282-288.
[http://dx.doi.org/10.1016/j.physbeh.2008.10.008] [PMID: 18977236]
[47]
Hanada, R.; Nakazato, M.; Murakami, N.; Sakihara, S.; Yoshimatsu, H.; Toshinai, K.; Hanada, T.; Suda, T.; Kangawa, K.; Matsukura, S.; Sakata, T. A role for neuromedin U in stress response. Biochem. Biophys. Res. Commun., 2001, 289(1), 225-228.
[http://dx.doi.org/10.1006/bbrc.2001.5945] [PMID: 11708803]
[48]
Wren, A.M.; Small, C.J.; Abbott, C.R.; Jethwa, P.H.; Kennedy, A.R.; Murphy, K.G.; Stanley, S.A.; Zollner, A.N.; Ghatei, M.A.; Bloom, S.R. Hypothalamic actions of neuromedin U. Endocrinology, 2002, 143(11), 4227-4234.
[http://dx.doi.org/10.1210/en.2002-220308] [PMID: 12399416]
[49]
Gartlon, J.; Szekeres, P.; Pullen, M.; Sarau, H.M.; Aiyar, N.; Shabon, U.; Michalovich, D.; Steplewski, K.; Ellis, C.; Elshourbagy, N.; Duxon, M.; Ashmeade, T.E.; Harrison, D.C.; Murdock, P.; Wilson, S.; Ennaceur, A.; Atkins, A.; Heidbreder, C.; Hagan, J.J.; Hunter, A.J.; Jones, D.N. Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats. Psychopharmacology (Berl.), 2004, 177(1-2), 1-14.
[http://dx.doi.org/10.1007/s00213-004-1918-3] [PMID: 15205870]
[50]
Niimi, M.; Murao, K.; Taminato, T. Central administration of neuromedin U activates neurons in ventrobasal hypothalamus and brainstem. Endocrine, 2001, 16(3), 201-206.
[http://dx.doi.org/10.1385/ENDO:16:3:201] [PMID: 11954664]
[51]
Ozaki, Y.; Onaka, T.; Nakazato, M.; Saito, J.; Kanemoto, K.; Matsumoto, T.; Ueta, Y. Centrally administered neuromedin U activates neurosecretion and induction of c-fos messenger ribonucleic acid in the paraventricular and supraoptic nuclei of rat. Endocrinology, 2002, 143(11), 4320-4329.
[http://dx.doi.org/10.1210/en.2002-220201] [PMID: 12399428]
[52]
Yokota, M.; Ozaki, Y.; Sakamoto, F.; Yamada, S.; Saito, J.; Fujihara, H.; Ueta, Y. Fos expression in CRF-containing neurons in the rat paraventricular nucleus after central administration of neuromedin U. Stress, 2004, 7(2), 109-112.
[http://dx.doi.org/10.1080/10253890410001727370] [PMID: 15512854]
[53]
Rokkaku, K.; Onaka, T.; Okada, N.; Ideno, J.; Kawakami, A.; Honda, K.; Yada, T.; Ishibashi, S. Neuromedin U facilitates oxytocin release from the pituitary via beta adrenoceptors. Neuroreport, 2003, 14(15), 1997-2000.
[http://dx.doi.org/10.1097/00001756-200310270-00024] [PMID: 14561937]
[54]
Sasaki, T.; Shimizu, T.; Wakiguchi, H.; Yokotani, K. Centrally administered neuromedin U elevates plasma adrenaline by brain prostanoid TP receptor-mediated mechanisms in rats. Eur. J. Pharmacol., 2008, 592(1-3), 81-86.
[http://dx.doi.org/10.1016/j.ejphar.2008.07.006] [PMID: 18647601]
[55]
Nakazato, M.; Hanada, R.; Murakami, N.; Date, Y.; Mondal, M.S.; Kojima, M.; Yoshimatsu, H.; Kangawa, K.; Matsukura, S. Central effects of neuromedin U in the regulation of energy homeostasis. Biochem. Biophys. Res. Commun., 2000, 277(1), 191-194.
[http://dx.doi.org/10.1006/bbrc.2000.3669] [PMID: 11027662]
[56]
Nakahara, K.; Katayama, T.; Maruyama, K.; Ida, T.; Mori, K.; Miyazato, M.; Kangawa, K.; Murakami, N. Comparison of feeding suppression by the anorexigenic hormones neuromedin U and neuromedin S in rats. J. Endocrinol., 2010, 207(2), 185-193.
[http://dx.doi.org/10.1677/JOE-10-0081] [PMID: 20732934]
[57]
Peier, A.; Kosinski, J.; Cox-York, K.; Qian, Y.; Desai, K.; Feng, Y.; Trivedi, P.; Hastings, N.; Marsh, D.J. The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2). Endocrinology, 2009, 150(7), 3101-3109.
[http://dx.doi.org/10.1210/en.2008-1772] [PMID: 19324999]
[58]
Ivanov, T.R.; Lawrence, C.B.; Stanley, P.J.; Luckman, S.M. Evaluation of neuromedin U actions in energy homeostasis and pituitary function. Endocrinology, 2002, 143(10), 3813-3821.
[http://dx.doi.org/10.1210/en.2002-220121] [PMID: 12239092]
[59]
Jethwa, P.H.; Small, C.J.; Smith, K.L.; Seth, A.; Darch, S.J.; Abbott, C.R.; Murphy, K.G.; Todd, J.F.; Ghatei, M.A.; Bloom, S.R. Neuromedin U has a physiological role in the regulation of food intake and partially mediates the effects of leptin. Am. J. Physiol. Endocrinol. Metab., 2005, 289(2), E301-E305.
[http://dx.doi.org/10.1152/ajpendo.00404.2004] [PMID: 16014357]
[60]
Peier, A.M.; Desai, K.; Hubert, J.; Du, X.; Yang, L.; Qian, Y.; Kosinski, J.R.; Metzger, J.M.; Pocai, A.; Nawrocki, A.R.; Langdon, R.B.; Marsh, D.J. Effects of peripherally administered neuromedin U on energy and glucose homeostasis. Endocrinology, 2011, 152(7), 2644-2654.
[http://dx.doi.org/10.1210/en.2010-1463] [PMID: 21586559]
[61]
McCue, D.L.; Kasper, J.M.; Hommel, J.D. Regulation of motivation for food by neuromedin U in the paraventricular nucleus and the dorsal raphe nucleus. Int. J. Obes., 2017, 41(1), 120-128.
[http://dx.doi.org/10.1038/ijo.2016.178] [PMID: 27748746]
[62]
Egecioglu, E.; Ploj, K.; Xu, X.; Bjursell, M.; Salomé, N.; Andersson, N.; Ohlsson, C.; Taube, M.; Hansson, C.; Bohlooly-Y, M.; Morgan, D.G.; Dickson, S.L. Central NMU signaling in body weight and energy balance regulation: evidence from NMUR2 deletion and chronic central NMU treatment in mice. Am. J. Physiol. Endocrinol. Metab., 2009, 297(3), E708-E716.
[http://dx.doi.org/10.1152/ajpendo.91022.2008] [PMID: 19584200]
[63]
Thompson, E.L.; Murphy, K.G.; Todd, J.F.; Martin, N.M.; Small, C.J.; Ghatei, M.A.; Bloom, S.R. Chronic administration of NMU into the paraventricular nucleus stimulates the HPA axis but does not influence food intake or body weight. Biochem. Biophys. Res. Commun., 2004, 323(1), 65-71.
[http://dx.doi.org/10.1016/j.bbrc.2004.08.058] [PMID: 15351702]
[64]
Zeng, H.; Gragerov, A.; Hohmann, J.G.; Pavlova, M.N.; Schimpf, B.A.; Xu, H.; Wu, L.J.; Toyoda, H.; Zhao, M.G.; Rohde, A.D.; Gragerova, G.; Onrust, R.; Bergmann, J.E.; Zhuo, M.; Gaitanaris, G.A. Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding. Mol. Cell. Biol., 2006, 26(24), 9352-9363.
[http://dx.doi.org/10.1128/MCB.01148-06] [PMID: 17030627]
[65]
Torres, R.; Croll, S.D.; Vercollone, J.; Reinhardt, J.; Griffiths, J.; Zabski, S.; Anderson, K.D.; Adams, N.C.; Gowen, L.; Sleeman, M.W.; Valenzuela, D.M.; Wiegand, S.J.; Yancopoulos, G.D.; Murphy, A.J. Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses. Pain, 2007, 130(3), 267-278.
[http://dx.doi.org/10.1016/j.pain.2007.01.036] [PMID: 17379411]
[66]
Cao, C.Q.; Yu, X.H.; Dray, A.; Filosa, A.; Perkins, M.N. A pro-nociceptive role of neuromedin U in adult mice. Pain, 2003, 104(3), 609-616.
[http://dx.doi.org/10.1016/S0304-3959(03)00118-0] [PMID: 12927633]
[67]
Yu, X.H.; Cao, C.Q.; Mennicken, F.; Puma, C.; Dray, A.; O’Donnell, D.; Ahmad, S.; Perkins, M. Pro-nociceptive effects of neuromedin U in rat. Neuroscience, 2003, 120(2), 467-474.
[http://dx.doi.org/10.1016/S0306-4522(03)00300-2] [PMID: 12890516]
[68]
Nakahara, K.; Kojima, M.; Hanada, R.; Egi, Y.; Ida, T.; Miyazato, M.; Kangawa, K.; Murakami, N. Neuromedin U is involved in nociceptive reflexes and adaptation to environmental stimuli in mice. Biochem. Biophys. Res. Commun., 2004, 323(2), 615-620.
[http://dx.doi.org/10.1016/j.bbrc.2004.08.136] [PMID: 15369794]
[69]
Johnson, E.N.; Appelbaum, E.R.; Carpenter, D.C.; Cox, R.F.; Disa, J.; Foley, J.J.; Ghosh, S.K.; Naselsky, D.P.; Pullen, M.A.; Sarau, H.M.; Scheff, S.R.; Steplewski, K.M.; Zaks-Zilberman, M.; Aiyar, N. Neuromedin U elicits cytokine release in murine Th2-type T cell clone D10.G4.1. J. Immunol., 2004, 173(12), 7230-7238.
[http://dx.doi.org/10.4049/jimmunol.173.12.7230] [PMID: 15585845]
[70]
Moriyama, M.; Fukuyama, S.; Inoue, H.; Matsumoto, T.; Sato, T.; Tanaka, K.; Kinjyo, I.; Kano, T.; Yoshimura, A.; Kojima, M. The neuropeptide neuromedin U activates eosinophils and is involved in allergen-induced eosinophilia. Am. J. Physiol. Lung Cell. Mol. Physiol., 2006, 290(5), L971-L977.
[http://dx.doi.org/10.1152/ajplung.00345.2005] [PMID: 16373672]
[71]
Moriyama, M.; Matsukawa, A.; Kudoh, S.; Takahashi, T.; Sato, T.; Kano, T.; Yoshimura, A.; Kojima, M. The neuropeptide neuromedin U promotes IL-6 production from macrophages and endotoxin shock. Biochem. Biophys. Res. Commun., 2006, 341(4), 1149-1154.
[http://dx.doi.org/10.1016/j.bbrc.2006.01.075] [PMID: 16466693]
[72]
Klose, C.S.N.; Mahlakõiv, T.; Moeller, J.B.; Rankin, L.C.; Flamar, A.L.; Kabata, H.; Monticelli, L.A.; Moriyama, S.; Putzel, G.G.; Rakhilin, N.; Shen, X.; Kostenis, E.; König, G.M.; Senda, T.; Carpenter, D.; Farber, D.L.; Artis, D. The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation. Nature, 2017, 549(7671), 282-286.
[http://dx.doi.org/10.1038/nature23676] [PMID: 28869965]
[73]
Cardoso, V.; Chesné, J.; Ribeiro, H.; García-Cassani, B.; Carvalho, T.; Bouchery, T.; Shah, K.; Barbosa-Morais, N.L.; Harris, N.; Veiga-Fernandes, H. Neuronal regulation of type 2 innate lymphoid cells via neuromedin U. Nature, 2017, 549(7671), 277-281.
[http://dx.doi.org/10.1038/nature23469] [PMID: 28869974]
[74]
Wallrapp, A.; Riesenfeld, S.J.; Burkett, P.R.; Abdulnour, R.E.; Nyman, J.; Dionne, D.; Hofree, M.; Cuoco, M.S.; Rodman, C.; Farouq, D.; Haas, B.J.; Tickle, T.L.; Trombetta, J.J.; Baral, P.; Klose, C.S.N.; Mahlakõiv, T.; Artis, D.; Rozenblatt-Rosen, O.; Chiu, I.M.; Levy, B.D.; Kowalczyk, M.S.; Regev, A.; Kuchroo, V.K. The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation. Nature, 2017, 549(7672), 351-356.
[http://dx.doi.org/10.1038/nature24029] [PMID: 28902842]
[75]
Nakahara, K.; Hanada, R.; Murakami, N.; Teranishi, H.; Ohgusu, H.; Fukushima, N.; Moriyama, M.; Ida, T.; Kangawa, K.; Kojima, M. The gut-brain peptide neuromedin U is involved in the mammalian circadian oscillator system. Biochem. Biophys. Res. Commun., 2004, 318(1), 156-161.
[http://dx.doi.org/10.1016/j.bbrc.2004.04.014] [PMID: 15110767]
[76]
Ahnaou, A.; Drinkenburg, W.H. Neuromedin U(2) receptor signaling mediates alteration of sleep-wake architecture in rats. Neuropeptides, 2011, 45(2), 165-174.
[http://dx.doi.org/10.1016/j.npep.2011.01.004] [PMID: 21296417]
[77]
Aizawa, S.; Sakata, I.; Nagasaka, M.; Higaki, Y.; Sakai, T. Negative regulation of neuromedin U mRNA expression in the rat pars tuberalis by melatonin. PLoS One, 2013, 8(7)e67118
[http://dx.doi.org/10.1371/journal.pone.0067118] [PMID: 23843987]
[78]
Chiu, C.N.; Rihel, J.; Lee, D.A.; Singh, C.; Mosser, E.A.; Chen, S.; Sapin, V.; Pham, U.; Engle, J.; Niles, B.J.; Montz, C.J.; Chakravarthy, S.; Zimmerman, S.; Salehi-Ashtiani, K.; Vidal, M.; Schier, A.F.; Prober, D.A. A zebrafish genetic screen identifies neuromedin U as a regulator of sleep/wake states. Neuron, 2016, 89(4), 842-856.
[http://dx.doi.org/10.1016/j.neuron.2016.01.007] [PMID: 26889812]
[79]
Graham, E.S.; Littlewood, P.; Turnbull, Y.; Mercer, J.G.; Morgan, P.J.; Barrett, P. Neuromedin-U is regulated by the circadian clock in the SCN of the mouse. Eur. J. Neurosci., 2005, 21(3), 814-819.
[http://dx.doi.org/10.1111/j.1460-9568.2005.03923.x] [PMID: 15733101]
[80]
Garczyk, S.; Klotz, N.; Szczepanski, S.; Denecke, B.; Antonopoulos, W.; von Stillfried, S.; Knüchel, R.; Rose, M.; Dahl, E. Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway. Oncotarget, 2017, 8(22), 36246-36265.
[http://dx.doi.org/10.18632/oncotarget.16121] [PMID: 28423716]
[81]
Ketterer, K.; Kong, B.; Frank, D.; Giese, N.A.; Bauer, A.; Hoheisel, J.; Korc, M.; Kleeff, J.; Michalski, C.W.; Friess, H. Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett., 2009, 277(1), 72-81.
[http://dx.doi.org/10.1016/j.canlet.2008.11.028] [PMID: 19118941]
[82]
Martinez, V.G.; Crown, J.; Porter, R.K.; O’Driscoll, L. Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer. Int. J. Cancer, 2017, 140(12), 2771-2784.
[http://dx.doi.org/10.1002/ijc.30705] [PMID: 28340506]
[83]
Przygodzka, P.; Papiewska-Pajak, I.; Bogusz, H.; Kryczka, J.; Sobierajska, K.; Kowalska, M.A.; Boncela, J. Neuromedin U is upregulated by Snail at early stages of EMT in HT29 colon cancer cells. Biochim. Biophys. Acta, 2016, 1860(11 Pt A), 2445-2453.
[http://dx.doi.org/10.1016/j.bbagen.2016.07.012] [PMID: 27450890]
[84]
Shetzline, S.E.; Rallapalli, R.; Dowd, K.J.; Zou, S.; Nakata, Y.; Swider, C.R.; Kalota, A.; Choi, J.K.; Gewirtz, A.M. Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood, 2004, 104(6), 1833-1840.
[http://dx.doi.org/10.1182/blood-2003-10-3577] [PMID: 15187020]
[85]
Wu, Y.; McRoberts, K.; Berr, S.S.; Frierson, H.F., Jr; Conaway, M.; Theodorescu, D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene, 2007, 26(5), 765-773.
[http://dx.doi.org/10.1038/sj.onc.1209835] [PMID: 16878152]
[86]
Nakahara, K.; Akagi, A.; Shimizu, S.; Tateno, S.; Qattali, A.W.; Mori, K.; Miyazato, M.; Kangawa, K.; Murakami, N. Involvement of endogenous neuromedin U and neuromedin S in thermoregulation. Biochem. Biophys. Res. Commun., 2016, 470(4), 930-935.
[http://dx.doi.org/10.1016/j.bbrc.2016.01.155] [PMID: 26826380]
[87]
Hanada, R.; Teranishi, H.; Pearson, J.T.; Kurokawa, M.; Hosoda, H.; Fukushima, N.; Fukue, Y.; Serino, R.; Fujihara, H.; Ueta, Y.; Ikawa, M.; Okabe, M.; Murakami, N.; Shirai, M.; Yoshimatsu, H.; Kangawa, K.; Kojima, M. Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat. Med., 2004, 10(10), 1067-1073.
[http://dx.doi.org/10.1038/nm1106] [PMID: 15448684]
[88]
Sato, S.; Hanada, R.; Kimura, A.; Abe, T.; Matsumoto, T.; Iwasaki, M.; Inose, H.; Ida, T.; Mieda, M.; Takeuchi, Y.; Fukumoto, S.; Fujita, T.; Kato, S.; Kangawa, K.; Kojima, M.; Shinomiya, K.; Takeda, S. Central control of bone remodeling by neuromedin U. Nat. Med., 2007, 13(10), 1234-1240.
[http://dx.doi.org/10.1038/nm1640] [PMID: 17873881]
[89]
Rucinski, M.; Ziolkowska, A.; Tyczewska, M.; Szyszka, M.; Malendowicz, L.K. Neuromedin U directly stimulates growth of cultured rat calvarial osteoblast-like cells acting via the NMU receptor 2 isoform. Int. J. Mol. Med., 2008, 22(3), 363-368.
[PMID: 18698496]
[90]
Gianfagna, F.; Cugino, D.; Ahrens, W.; Bailey, M.E.; Bammann, K.; Herrmann, D.; Koni, A.C.; Kourides, Y.; Marild, S.; Molnár, D.; Moreno, L.A.; Pitsiladis, Y.P.; Russo, P.; Siani, A.; Sieri, S.; Sioen, I.; Veidebaum, T.; Iacoviello, L. Understanding the links among neuromedin U gene, beta2-adrenoceptor gene and bone health: an observational study in European children. PLoS One, 2013, 8(8)e70632
[http://dx.doi.org/10.1371/journal.pone.0070632] [PMID: 23936460]
[91]
Fukue, Y.; Sato, T.; Teranishi, H.; Hanada, R.; Takahashi, T.; Nakashima, Y.; Kojima, M. Regulation of gonadotropin secretion and puberty onset by neuromedin U. FEBS Lett., 2006, 580(14), 3485-3488.
[http://dx.doi.org/10.1016/j.febslet.2006.05.025] [PMID: 16716306]
[92]
Vigo, E.; Roa, J.; Pineda, R.; Castellano, J.M.; Navarro, V.M.; Aguilar, E.; Pinilla, L.; Tena-Sempere, M. Novel role of the anorexigenic peptide neuromedin U in the control of LH secretion and its regulation by gonadal hormones and photoperiod. Am. J. Physiol. Endocrinol. Metab., 2007, 293(5), E1265-E1273.
[http://dx.doi.org/10.1152/ajpendo.00425.2007] [PMID: 17726140]
[93]
Quan, H.; Funabashi, T.; Furuta, M.; Kimura, F. Effects of neuromedin U on the pulsatile LH secretion in ovariectomized rats in association with feeding conditions. Biochem. Biophys. Res. Commun., 2003, 311(3), 721-727.
[http://dx.doi.org/10.1016/j.bbrc.2003.10.052] [PMID: 14623332]
[94]
Grippi, C.; Izzi, B.; Gianfagna, F.; Noro, F.; Falcinelli, E.; Di Pardo, A.; Amico, E.; Donati, M.B.; de Gaetano, G.; Iacoviello, L.; Hoylaerts, M.F.; Cerletti, C. Neuromedin U potentiates ADP- and epinephrine-induced human platelet activation. Thromb. Res., 2017, 159, 100-108.
[http://dx.doi.org/10.1016/j.thromres.2017.09.027] [PMID: 29078099]
[95]
Vallöf, D.; Vestlund, J.; Engel, J.A.; Jerlhag, E. The anorexigenic peptide neuromedin U (NMU) attenuates amphetamine-induced locomotor stimulation, accumbal dopamine release and expression of conditioned place preference in mice. PLoS One, 2016, 11(5)e0154477
[http://dx.doi.org/10.1371/journal.pone.0154477] [PMID: 27139195]
[96]
Vallöf, D.; Ulenius, L.; Egecioglu, E.; Engel, J.A.; Jerlhag, E. Central administration of the anorexigenic peptide neuromedin U decreases alcohol intake and attenuates alcohol-induced reward in rodents. Addict. Biol., 2017, 22(3), 640-651.
[http://dx.doi.org/10.1111/adb.12355] [PMID: 26769653]
[97]
Sakura, N.; Kurosawa, K.; Hashimoto, T. Structure-activity relationships of neuromedin U. I. Contractile activity of dog neuromedin U-related peptides on isolated chicken crop smooth muscle. Chem. Pharm. Bull. (Tokyo), 1995, 43(7), 1148-1153.
[http://dx.doi.org/10.1248/cpb.43.1148] [PMID: 7586058]
[98]
Sakura, N.; Ohta, S.; Uchida, Y.; Kurosawa, K.; Okimura, K.; Hashimoto, T. Structure-activity relationships of rat neuromedin U for smooth muscle contraction. Chem. Pharm. Bull. (Tokyo), 1991, 39(8), 2016-2020.
[http://dx.doi.org/10.1248/cpb.39.2016] [PMID: 1797423]
[99]
Kawai, T.; Shibata, A.; Kurosawa, K.; Sato, Y.; Kato, S.; Ohki, K.; Hashimoto, T.; Sakura, N. Structure-activity relationships of neuromedin U. V. study on the stability of porcine neuromedin U-8 at the C-terminal asparagine amide under mild alkaline and acidic conditions. Chem. Pharm. Bull. (Tokyo), 2006, 54(5), 659-664.
[http://dx.doi.org/10.1248/cpb.54.659] [PMID: 16651761]
[100]
Hashimoto, T.; Masui, H.; Uchida, Y.; Sakura, N.; Okimura, K. Agonistic and antagonistic activities of neuromedin U-8 analogs substituted with glycine or D-amino acid on contractile activity of chicken crop smooth muscle preparations. Chem. Pharm. Bull. (Tokyo), 1991, 39(9), 2319-2322.
[http://dx.doi.org/10.1248/cpb.39.2319] [PMID: 1804545]
[101]
Tsubota, Y.; Kakimoto, N.; Owada-Makabe, K.; Yukawa, K.; Liang, X.M.; Mune, M.; Maeda, M. Hypotensive effects of neuromedin U microinjected into the cardiovascular-related region of the rat nucleus tractus solitarius. Neuroreport, 2003, 14(18), 2387-2390.
[http://dx.doi.org/10.1097/00001756-200312190-00020] [PMID: 14663197]
[102]
Hashimoto, T.; Kurosawa, K.; Sakura, N. Structure-activity relationships of neuromedin U. II. Highly potent analogs substituted or modified at the N-terminus of neuromedin U-8. Chem. Pharm. Bull. (Tokyo), 1995, 43(7), 1154-1157.
[http://dx.doi.org/10.1248/cpb.43.1154] [PMID: 7586059]
[103]
Kurosawa, K.; Sakura, N.; Hashimoto, T. Structure-activity relationships of neuromedin U. III. Contribution of two phenylalanine residues in dog neuromedin U-8 to the contractile activity. Chem. Pharm. Bull. (Tokyo), 1996, 44(10), 1880-1884.
[http://dx.doi.org/10.1248/cpb.44.1880] [PMID: 8904815]
[104]
Sakura, N.; Kurosawa, K.; Hashimoto, T. Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity. Chem. Pharm. Bull. (Tokyo), 2000, 48(8), 1166-1170.
[http://dx.doi.org/10.1248/cpb.48.1166] [PMID: 10959581]
[105]
Abiko, T.; Takamura, Y. Syntheses of two neuromedin U (NMU) analogues and their comparative reducing food intake effect in rats. Amino Acids, 2003, 25(1), 107-110.
[http://dx.doi.org/10.1007/s00726-002-0351-3] [PMID: 12836065]
[106]
Ingallinella, P.; Peier, A.M.; Pocai, A.; Marco, A.D.; Desai, K.; Zytko, K.; Qian, Y.; Du, X.; Cellucci, A.; Monteagudo, E.; Laufer, R.; Bianchi, E.; Marsh, D.J.; Pessi, A. PEGylation of neuromedin U yields a promising candidate for the treatment of obesity and diabetes. Bioorg. Med. Chem., 2012, 20(15), 4751-4759.
[http://dx.doi.org/10.1016/j.bmc.2012.06.003] [PMID: 22771182]
[107]
Zhang, F.; Liu, M.R.; Wan, H.T. Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol. Pharm. Bull., 2014, 37(3), 335-339.
[http://dx.doi.org/10.1248/bpb.b13-00661] [PMID: 24334536]
[108]
Neuner, P.; Peier, A.M.; Talamo, F.; Ingallinella, P.; Lahm, A.; Barbato, G.; Di Marco, A.; Desai, K.; Zytko, K.; Qian, Y.; Du, X.; Ricci, D.; Monteagudo, E.; Laufer, R.; Pocai, A.; Bianchi, E.; Marsh, D.J.; Pessi, A. Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide. J. Pept. Sci., 2014, 20(1), 7-19.
[http://dx.doi.org/10.1002/psc.2582] [PMID: 24222478]
[109]
Larsen, M.T.; Kuhlmann, M.; Hvam, M.L.; Howard, K.A. Albumin-based drug delivery: harnessing nature to cure disease. Mol. Cell. Ther., 2016, 4, 3.
[http://dx.doi.org/10.1186/s40591-016-0048-8] [PMID: 26925240]
[110]
Dalbøge, L.S.; Pedersen, S.L.; van Witteloostuijn, S.B.; Rasmussen, J.E.; Rigbolt, K.T.; Jensen, K.J.; Holst, B.; Vrang, N.; Jelsing, J. Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake. J. Pept. Sci., 2015, 21(2), 85-94.
[http://dx.doi.org/10.1002/psc.2727] [PMID: 25521062]
[111]
Dalbøge, L.S.; Pedersen, S.L.; Secher, T.; Holst, B.; Vrang, N.; Jelsing, J. Neuromedin U inhibits food intake partly by inhibiting gastric emptying. Peptides, 2015, 69, 56-65.
[http://dx.doi.org/10.1016/j.peptides.2015.04.010] [PMID: 25895852]
[112]
Sasaki-Hamada, S.; Funane, T.; Nakao, Y.; Sasaki, R.; Nagai, M.; Ueta, Y.; Yoshizawa, K.; Horiguchi, M.; Yamashita, C.; Oka, J.I. Intranasal administration of neuromedin U derivatives containing cell-penetrating peptides and a penetration-accelerating sequence induced memory improvements in mice. Peptides, 2018, 99, 241-246.
[http://dx.doi.org/10.1016/j.peptides.2017.10.010] [PMID: 29079533]
[113]
Walrave, L.; Vinken, M.; Albertini, G.; De Bundel, D.; Leybaert, L.; Smolders, I.J. Inhibition of connexin43 hemichannels impairs spatial short-term memory without affecting spatial working memory. Front. Cell. Neurosci., 2016, 10, 288.
[http://dx.doi.org/10.3389/fncel.2016.00288] [PMID: 28066184]
[114]
Funes, S.; Hedrick, J.A.; Yang, S.; Shan, L.; Bayne, M.; Monsma, F.J. Jr.; Gustafson, E.L. Cloning and characterization of murine neuromedin U receptors. Peptides, 2002, 23(9), 1607-1615.
[http://dx.doi.org/10.1016/S0196-9781(02)00097-9] [PMID: 12217421]
[115]
Takayama, K.; Mori, K.; Taketa, K.; Taguchi, A.; Yakushiji, F.; Minamino, N.; Miyazato, M.; Kangawa, K.; Hayashi, Y. Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2. J. Med. Chem., 2014, 57(15), 6583-6593.
[http://dx.doi.org/10.1021/jm500599s] [PMID: 24999562]
[116]
Takayama, K.; Mori, K.; Sohma, Y.; Taketa, K.; Taguchi, A.; Yakushiji, F.; Minamino, N.; Miyazato, M.; Kangawa, K.; Hayashi, Y. Discovery of potent hexapeptide agonists to human neuromedin u receptor 1 and identification of their serum metabolites. ACS Med. Chem. Lett., 2015, 6(3), 302-307.
[http://dx.doi.org/10.1021/ml500494j] [PMID: 25815150]
[117]
Takayama, K.; Mori, K.; Tanaka, A.; Nomura, E.; Sohma, Y.; Mori, M.; Taguchi, A.; Taniguchi, A.; Sakane, T.; Yamamoto, A.; Minamino, N.; Miyazato, M.; Kangawa, K.; Hayashi, Y. Discovery of a human neuromedin U receptor 1-selective hexapeptide agonist with enhanced serum stability. J. Med. Chem., 2017, 60(12), 5228-5234.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00694] [PMID: 28548497]
[118]
Micewicz, E.D.; Bahattab, O.S.; Willars, G.B.; Waring, A.J.; Navab, M.; Whitelegge, J.P.; McBride, W.H.; Ruchala, P. Small lipidated anti-obesity compounds derived from neuromedin U. Eur. J. Med. Chem., 2015, 101, 616-626.
[http://dx.doi.org/10.1016/j.ejmech.2015.07.020] [PMID: 26204509]
[119]
Masuda, Y.; Kumano, S.; Noguchi, J.; Sakamoto, K.; Inooka, H.; Ohtaki, T. PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration. Peptides, 2017, 94, 99-105.
[http://dx.doi.org/10.1016/j.peptides.2017.04.001] [PMID: 28400225]
[120]
Inooka, H.; Sakamoto, K.; Shinohara, T.; Masuda, Y.; Terada, M.; Kumano, S.; Yokoyama, K.; Noguchi, J.; Nishizawa, N.; Kamiguchi, H.; Fujita, H.; Asami, T.; Takekawa, S.; Ohtaki, T. A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects. Bioorg. Med. Chem., 2017, 25(8), 2307-2312.
[http://dx.doi.org/10.1016/j.bmc.2017.02.023] [PMID: 28291683]
[121]
Kanematsu-Yamaki, Y.; Nishizawa, N.; Kaisho, T.; Nagai, H.; Mochida, T.; Asakawa, T.; Inooka, H.; Dote, K.; Fujita, H.; Matsumiya, K.; Hirabayashi, H.; Sakamoto, J.; Ohtaki, T.; Takekawa, S.; Asami, T. Potent body weight-lowering effect of a neuromedin U receptor 2-selective PEGylated peptide. J. Med. Chem., 2017, 60(14), 6089-6097.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00330] [PMID: 28657315]
[122]
Kaisho, T.; Nagai, H.; Asakawa, T.; Suzuki, N.; Fujita, H.; Matsumiya, K.; Nishizawa, N.; Kanematsu-Yamaki, Y.; Dote, K.; Sakamoto, J.I.; Asami, T.; Takekawa, S. Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice. Int. J. Obes., 2017, 41(12), 1790-1797.
[http://dx.doi.org/10.1038/ijo.2017.176] [PMID: 28757640]
[123]
Nishizawa, N.; Kanematsu-Yamaki, Y.; Funata, M.; Nagai, H.; Shimizu, A.; Fujita, H.; Sakamoto, J.; Takekawa, S.; Asami, T. A potent neuromedin U receptor 2-selective alkylated peptide. Bioorg. Med. Chem. Lett., 2017, 27(20), 4626-4629.
[http://dx.doi.org/10.1016/j.bmcl.2017.09.019] [PMID: 28935264]
[124]
De Prins, A.; Martin, C.; Van Wanseele, Y.; Skov, L.J.; Tömböly, C.; Tourwé, D.; Caveliers, V.; Van Eeckhaut, A.; Holst, B.; Rosenkilde, M.M.; Smolders, I.; Ballet, S. Development of potent and proteolytically stable human neuromedin U receptor agonists. Eur. J. Med. Chem., 2018, 144, 887-897.
[http://dx.doi.org/10.1016/j.ejmech.2017.12.035] [PMID: 29329072]
[125]
De Prins, A.; Martin, C.; Van Wanseele, Y.; Tömböly, C.; Tourwé, D.; Caveliers, V.; Holst, B.; Van Eeckhaut, A.; Rosenkilde, M.M.; Smolders, I.; Ballet, S. Synthesis and in vitro evaluation of stabilized and selective neuromedin U-1 receptor agonists. ACS Med. Chem. Lett., 2018, 9(5), 496-501.
[http://dx.doi.org/10.1021/acsmedchemlett.8b00105] [PMID: 29795766]
[126]
Liu, J.J.; Payza, K.; Huang, J.; Liu, R.; Chen, T.; Coupal, M.; Laird, J.M.; Cao, C.Q.; Butterworth, J.; Lapointe, S.; Bayrakdarian, M.; Trivedi, S.; Bostwick, J.R. Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2. J. Pharmacol. Exp. Ther., 2009, 330(1), 268-275.
[http://dx.doi.org/10.1124/jpet.109.152967] [PMID: 19369576]
[127]
Zheng, X.; Hu, Y.; Liu, J.; Ouyang, K. Screening of active compounds as neuromedin U2 receptor agonist from natural products. Bioorg. Med. Chem. Lett., 2005, 15(20), 4531-4535.
[http://dx.doi.org/10.1016/j.bmcl.2005.07.003] [PMID: 16111886]
[128]
Fang, L.; Zhang, M.; Li, C.; Dong, S.; Hu, Y. Chemical genetic analysis reveals the effects of NMU2R on the expression of peptide hormones. Neurosci. Lett., 2006, 404(1-2), 148-153.
[http://dx.doi.org/10.1016/j.neulet.2006.05.034] [PMID: 16781063]
[129]
Meng, T.; Su, H.R.; Binkert, C.; Fischli, W.; Zhou, L.; Shen, J.K.; Wang, M.W. Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay. Acta Pharmacol. Sin., 2008, 29(4), 517-527.
[http://dx.doi.org/10.1111/j.1745-7254.2008.00769.x] [PMID: 18358099]
[130]
Sampson, C.M.; Kasper, J.M.; Felsing, D.E.; Raval, S.R.; Ye, N.; Wang, P.; Patrikeev, I.; Rytting, E.; Zhou, J.; Allen, J.A.; Hommel, J.D. Small-molecule neuromedin U receptor 2 agonists suppress food intake and decrease visceral fat in animal models. Pharmacol. Res. Perspect., 2018, 6(5)e00425
[http://dx.doi.org/10.1002/prp2.425] [PMID: 30151213]
[131]
Ma, M.L.; Li, M.; Gou, J.J.; Ruan, T.Y.; Jin, H.S.; Zhang, L.H.; Wu, L.C.; Li, X.Y.; Hu, Y.H.; Wen, K.; Zhao, Z. Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor. Bioorg. Med. Chem., 2014, 22(21), 6117-6123.
[http://dx.doi.org/10.1016/j.bmc.2014.08.038] [PMID: 25262941]
[132]
Zheng, X.; Guo, L.; Wang, D.; Deng, X. p-Synephrine: a novel agonist for neuromedin U2 receptor. Biol. Pharm. Bull., 2014, 37(5), 764-770.
[http://dx.doi.org/10.1248/bpb.b13-00788] [PMID: 24598981]
[133]
Nagai, H.; Kaisho, T.; Yokoyama, K.; Asakawa, T.; Fujita, H.; Matsumiya, K.; Noguchi, J.; Tsuchimori, K.; Nishizawa, N.; Kanematsu-Yamaki, Y.; Dote, K.; Inooka, H.; Sakamoto, J.I.; Ohtaki, T.; Asami, T.; Takekawa, S. Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice. Br. J. Pharmacol., 2018, 175(2), 359-373.
[http://dx.doi.org/10.1111/bph.14077] [PMID: 29057457]

Rights & Permissions Print Cite
Article Metrics
50
5
© 2024 Bentham Science Publishers | Privacy Policy